Liver transplant for HCC still works well past 65 -- age alone shouldn't be a dealbreaker.
Saad Alghamdi, Dimitri Aristotle Raptis, Lina Aljurf, et al.
Reviewing 244 liver transplant recipients with hepatocellular carcinoma over two decades, researchers found that patients over 65 fared only modestly worse than younger recipients, with five-year survival still around 89%. Most received living-donor grafts and pre-transplant treatments such as radiofrequency ablation or chemoembolization, and in-hospital mortality was low across the cohort. The authors conclude that chronological age by itself should not exclude older HCC patients from transplant evaluation.
- The question: Should age alone rule out liver transplantation for HCC?
- The study: Researchers reviewed 244 liver transplant recipients with hepatocellular carcinoma, followed over two decades.
- The finding: Patients over 65 fared only modestly worse than younger recipients — five-year survival was still around 89%.
- The nuance: Most received living-donor grafts and pre-transplant treatments like ablation or chemoembolization, and in-hospital mortality stayed low across the cohort.
Takeaway: chronological age alone should not exclude older HCC patients from transplant evaluation.
Narrated (standard AI voice, not a cloned voice) with burned-in captions matching the narration word-for-word — safe to watch muted. Built from this article’s SGA Briefing only.
This links to the publisher’s open-access copy of record. A self-hosted PDF will appear here once one is on file.